Get in touch
Send an email
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique.
Thank you! Your submission has been received!
Oops! Please try again.
Maybe later...
Questions?
You can also call us on +31 404 300 443

LATEST NEWS

November 24, 2020
Announcing Research Collaboration with Janssen
Under the terms of the agreement, Janssen will have the exclusive option to research, develop and commercialize novel biological therapeutic candidates based on Symvivo’s bacTRL™ platform technology.
Read more...
November 5, 2020
CTV News - Symvivo's COVID-19 vaccine candidate begins clinical trial in Australia
Symvivo CEO and founder Alexander Graves told CTVNews.ca the vaccine candidate has a scientific and compliance benefit.
Read more...
November 2, 2020
First Healthy Volunteer Dosed in Phase 1 Clinical Trial of Symvivo's Oral COVID-19 Vaccine Candidate
Symvivo announces the enrollment and dosing of the first healthy volunteer in a clinical trial in Australia evaluating its bacTRL-Spike™ oral vaccine candidate for the prevention of COVID-19.
Read more...

TOPICS

Announcements
News
HOMEcovid-19bactrlAPPLICATIONSPIPELINEABOUTnews
Copyright @2020 Symvivo
|
Designed to matter by Bemoved Media